HMGCR and breast carcinoma: It is well-accepted that the mevalonate pathway drives malignant transformation [7,13,14] and since statins are well-established drugs used to lower serum cholesterol in patients, inhibiting the HMGCR [15], several studies have been performed to show that statins exert antitumor effects in human malignancies, including breast cancer [16,17].